tbuckley/cabot-search huggingface dataset:
HEARTMATE 6: BRIDGE TO HEART TRANSPLANTATION UTILIZING BIVENTRICULAR SUPPORT FOR CARDIOGENIC SHOCK
Authors: Mohan Satish, David Power, Umesh K. Gidwani, Noah Moss, Sumeet S. Mitter, Anelechi Anyanwu, Anuradha Lala, Donna M. Mancini
Journal: Journal of the American College of Cardiology (2022)
CLO22-066: Toxicity of a Modified PEG-Asparaginase Based SMILE Regimen is Comparable to L-Asparaginase Based SMILE in a non-Asian Population
Authors: Yiseiry Perez Melendez, A Mahmoud, R Caddell, R Nelson, L Sokol, B Shah, H Saeed
Journal: Journal of the National Comprehensive Cancer Network (2022)

"CLO22-066: Toxicity of a Modified PEG-Asparaginase Based SMILE Regimen is Comparable to L-Asparaginase Based SMILE in a non-Asian Population" published on 31 Mar 2022 by National Comprehensive Cancer Network.
EARLY EPINEPHRINE INFUSION PREVENTS LATE MYOCARDIAL DEPRESSION AND ACCELERATES CARDIAC RECOVERY IN A LARGE ANIMAL MODEL OF SEPTIC SHOCK
Authors: Verity Ford, Willard Applefeld, Jeffrey Wang, Junfeng Sun, Jing Feng, Robert L. Danner, Steve B. Solomon, Marcus Y. Chen, Stanislav Sidenko, Vandana Sachdev, Michael A. Solomon, Zu-Xi Yu, Charles Natanson
Journal: Journal of the American College of Cardiology (2022)
Fetal Therapies and Clinical Research: Beyond Risk and Benefit
Authors: Lesha D. Shah, John Lantos, Cara Hunt, Andrew McFadyen, Rafael Escandon, Alison Bateman-House
Journal: The American Journal of Bioethics (2022)

This article refers to:A New Ethical Framework for Assessing the Unique Challenges of Fetal Therapy TrialsConsidering Reprogenomics in the Ethical Future of Fetal Therapy TrialsConsents (and Contents) Under Pressure: Maintaining Space for Moral Engagement in Research ProtocolsMaternal-Fetal Therapy: The (Psycho)Social DilemmaWhat Lies Beneath the Framework: The Importance of Grounding Ethical Discussions of Maternal-Fetal TherapyMultidisciplinary Ethics Review for Liminal Cases in Maternal-Fetal Surgery: A ModelRestrictions on Abortion, Social Justice and the Ethics of Research in Maternal-Fetal Therapy Trials
Abstract P3-14-03: The DNA damage repair landscape in Black women with breast cancer
Authors: Aloran Mazumder, Athena Jimenez, Rachel E Ellsworth, Sophia George, Stephen J Freedland, Matthew N Bainbridge, Svasti Haricharan
Journal: Cancer Research (2022)

Abstract Black women have 42% higher mortality rate from estrogen receptor positive (ER+) breast cancer than white women. Molecular mechanisms underlying worse outcome in black women are understudied. Recently, downregulation of specific DNA damage repair (DDR) genes was shown to causally induce resistance to standard care endocrine therapy by dysregulating cell cycle regulation, and to associate with poor outcome in white women with ER+ breast cancer. However, frequency and patterns of DDR dysregulation in Black women with ER+ breast cancer and impact on survival outcomes remains untested. By assessing RNA expression of 104 DDR genes across three tumor, and two normal breast, datasets, here, we map for the first time, global patterns of DDR gene expression regulation specific to Black women, both in tumors and in the normal breast. We identify a specific subset of 8 candidate DDR genes that are dysregulated at the RNA level in tumors from Black women. Of note, a novel DDR regulation signature where genes from the homologous recombination pathway are upregulated and genes from SSBR pathways (mainly base excision repair) are coincidently downregulated is almost uniquely detectable in tumors from Black women (8% incidence relative to 1% in tumors from white women, p=0.01). Moreover, this coincident DDR signature associates with dysregulated cell cycle gene expression (p&amp;lt;0.001). In accordance, patients whose tumors demonstrate this coincident DDR signature also have significantly worse survival outcomes across datasets (hazard ratio of 9.5, p&amp;lt;0.001). Overall, these results constitute the first systematic analysis of differences in DDR gene expression regulation between Black and white women and identify a specific DDR signature associated with poor outcome in tumors from Black women. These results provide new grounds for refining biomarker profiles and improving precision medicine for underserved populations. Citation Format: Aloran Mazumder, Athena Jimenez, Rachel E Ellsworth, Sophia George, Stephen J Freedland, Matthew N Bainbridge, Svasti Haricharan. The DNA damage repair landscape in Black women with breast cancer [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-14-03.
Abstract P3-12-18: Mortality after late breast cancer recurrence in Denmark
Authors: Rikke Noergaard Pedersen, Lene Mellemkjær, Bent Ejlertsen, Mette Nørgaard, Deirdre Cronin-Fenton
Journal: Cancer Research (2022)

Abstract Purpose: Late recurrence (i.e., ≥10 years after primary diagnosis) may have a more favorable prognosis than earlier recurrence. We investigated the risk of breast cancer (BC) death after late recurrence and identified prognostic factors. Furthermore, we compared survival between late and early recurrence. Methods: Using the Danish Breast Cancer Group and other nationwide databases, we identified women with early or late BC recurrence during 2004-2018, who were alive 6 months after recurrence. We followed them until BC death, death from other causes, emigration, ten years or 31/12/2018. We calculated mortality rates (MRs) per 1000 person-years (PY) and cumulative BC mortality, for early versus late recurrence and by characteristics of the primary tumor and of the late recurrence. Using Cox regression, we calculated adjusted hazard ratios (HRs) for BC death, accounting for death from other causes as competing risk. Results: Among 2,004 patients with late recurrence, 721 died of BC with a median survival time of 3 years (MR= 84.8 per 1000 PY; 10-year cumulative mortality=50%). Among 1,573 patients with early recurrence, 1,092 BC deaths occurred with a median survival time of 2.6 years (MR= 173.9 per 1000 PY; 10-year cumulative mortality=72%). Advanced stage at primary diagnosis, distant metastases, and adjuvant recurrence treatments were associated with increased mortality, while breast-conserving surgery at primary diagnosis, loco-regional recurrence, and recurrence surgery were associated with lower mortality. Conclusion: Patients with late recurrence had a more favorable prognosis than patients with early recurrence. The localization of recurrent disease was the main prognostic factor for BC death. Citation Format: Rikke Noergaard Pedersen, Lene Mellemkjær, Bent Ejlertsen, Mette Nørgaard, Deirdre Cronin-Fenton. Mortality after late breast cancer recurrence in Denmark [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-12-18.
Identification and Management of Pathogenic Variants in<i>BRCA1</i>,<i>BRCA2</i>, and<i>PALB2</i>in a Tumor-Only Genomic Testing Program
Authors: Brittany L. Bychkovsky, Tianyu Li, Jilliane Sotelo, Nabihah Tayob, Joanna Mercado, Israel Gomy, Anu Chittenden, Sarah Kane, Samantha Stokes, Melissa E. Hughes, Ji Seok Kim, Renato Umeton, Mark M. Awad, Panagiotis A. Konstantinopoulos, Matthew B. Yurgelun, Brian M. Wolpin, Mary-Ellen Taplin, Randall E. Newmark, Bruce E. Johnson, Neal I. Lindeman, Laura E. MacConaill, Judy E. Garber, Nancy U. Lin
Journal: Clinical Cancer Research (2022)

Abstract Purpose: Tumor-only genomic testing can uncover somatic and germline pathogenic variants [pathogenic/likely pathogenic (P/LP)] in cancer predisposition genes. We describe the prevalence of P/LPs in BRCA1/2 and PALB2 (B1B2P2) across malignancies and the frequency of clinical germline testing (CGT) in patients with P/LPs in B1B2P2 identified on tumor-only testing. Experimental Design: Among 7,575 patients with cancer tested between 2016 and 2018 with the OncoPanel tumor-only sequencing assay, we characterized P/LP frequencies by tumor type, receipt of CGT prior to or within 12 months after OncoPanel, and factors associated with CGT. Results: 272 (3.6%) patients had OncoPanel-detected P/LPs in B1B2P2: 37.5% of P/LPs were in BRCA-related cancers; the remainder were in non-BRCA tumors. P/LPs were detected in ≥5% of breast, pancreatic, prostate, ovarian, nonmelanoma skin, endometrial, small cell lung, and colorectal cancers. 37.9% of patients with P/LPs received CGT prior to OncoPanel; an additional 10.7% underwent CGT within 12 months of OncoPanel. Among 132 with CGT, 88.6% had ≥1 clinical factor for CGT compared with 47.1% who did not undergo CGT. Patients with BRCA tumors were more likely to have CGT compared with those without (81.4% vs. 29.0%, P &amp;lt; 0.0001). Among patients with CGT, 70.5% (93/132) of P/LPs were germline. Conclusions: Tumor-only genomic testing identified P/LPs in B1B2P2 in 3.6% of patients. 52.9% of patients with tumor-detected P/LPs and without CGT did not meet personal or family history criteria for CGT. In addition, some patients with tumor-detected P/LPs were not referred for CGT, especially those with non-BRCA tumors. Given implications for treatment selection and familial cancer risk, processes to reliably trigger CGT from tumor-genomic findings are needed.
ONE SWAP AND TWO CLIPS: USE OF MITRACLIP FOR SEVERE TRICUSPID REGURGITATION IN A PATIENT WITH D-TRANSPOSITION OF THE GREAT ARTERIES
Authors: Marwah Shahid, Marcella A. Calfon-Press, Jeannette P. Lin, Jamil A. Aboulhosn
Journal: Journal of the American College of Cardiology (2022)
Abstract P1-12-01: Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: Final long-term results of the hellenic cooperative oncology group phase III HE10/05 trial
Authors: Flora Zagouri, Georgia-Angeliki Koliou, Foteinos Dimitrakopoulos, Christos Papadimitriou, Ioannis Binas, Angelos Koutras, Pavlos Papakostas, Christos Markopoulos, Vasileios Venizelos, Grigorios Xepapadakis, Charisios Karanikiotis, Amanda Psyrri, Dimitrios Bafaloukos, Paris Kosmidis, Gerasimos Aravantinos, Eleni Res, Davide Mauri, Anna Koumarianou, Kalliopi Petraki, Anna Tsipoura, Dimitrios Pectasides, Helen Gogas, George Fountzilas
Journal: Cancer Research (2022)

Abstract Background: Dose-dense sequential chemotherapy based on anthracyclines and taxanes has achieved an 18% reduction of recurrence risk in the adjuvant setting of early breast cancer (BC). However, the optimal chemotherapy schedule and the preferable interval between cycles are still under investigation. Methods: A total of 990 eligible BC patients were randomized to receive either 3 cycles of epirubicin (E,110 mg/m2) every 2 weeks followed by 3 cycles of paclitaxel (T, 200 mg/m2) every 2 weeks followed by 3 cycles of intensified CMF (Control Arm A, E-T-CMF; 333 patients) or three cycles of epirubicin followed by 3 cycles of CMF followed by 9 consecutive weekly cycles of docetaxel (wD) 35 mg/m2 (Experimental Arm B, E-CMF-wD; 331) or 9 consecutive weekly cycles of paclitaxel (wT) 80 mg/m2 (Experimental Arm C, E-CMF-wT; 326). Trastuzumab was administered for HER2-positive disease. The primary endpoint was disease-free survival (DFS). Results: At a median follow-up of 13.3 years, 330 DFS events (33.3%) had been reported. DFS and overall survival (OS) did not differ between patients in the combined B and C arms versus control arm A either in the entire cohort (HR=0.90, p=0.38 and HR=0.85, p=0.20) or among HER2-positive, trastuzumab-treated patients (HR=0.69, p=0.13 and HR=0.67, p=0.13). Thirty-four patients (3.4%) developed secondary neoplasms. Conclusions: Overall, no significant differences in DFS or OS were found amongst the studied regimens after a long-term observational period. Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12610000151033 Citation Format: Flora Zagouri, Georgia-Angeliki Koliou, Foteinos Dimitrakopoulos, Christos Papadimitriou, Ioannis Binas, Angelos Koutras, Pavlos Papakostas, Christos Markopoulos, Vasileios Venizelos, Grigorios Xepapadakis, Charisios Karanikiotis, Amanda Psyrri, Dimitrios Bafaloukos, Paris Kosmidis, Gerasimos Aravantinos, Eleni Res, Davide Mauri, Anna Koumarianou, Kalliopi Petraki, Anna Tsipoura, Dimitrios Pectasides, Helen Gogas, George Fountzilas. Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: Final long-term results of the hellenic cooperative oncology group phase III HE10/05 trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P1-12-01.
BALANCING MITOCHONDRIAL DYNAMICS VIA PHARMACOLOGICALINHIBITION OFFISSION PROTEIN PROTECTS THE HEART AGAINSTCHRONIC MYOCARDIAL INFARCTIONBY PRESERVATION OF MITOCHONDRIAL FUNCTION IN RATS
Authors: Chanon Piamsiri, Kewarin Jinawong, Chayodom Maneechote, Siriporn Chattipakorn, Nipon Chattipakorn
Journal: Journal of the American College of Cardiology (2022)
REDUCING ALL-CAUSE READMISSIONS FOR PATIENTS PRESENTING WITH ACUTE HEART FAILURE EXACERBATIONS: A QUALITY IMPROVEMENT INITIATIVE
Authors: Prem Patel, Nirmal Guragai, Biren D. Patel, Rajkumar Doshi, Kevin J. Hosein, Habib Habib, Firas Qaqa, Chirag Rana, Mary Donna Mananghaya Cruz, Fayez E. Shamoon
Journal: Journal of the American College of Cardiology (2022)
A DATA-DRIVEN CLUSTER ANALYSIS TO IDENTIFY SUBGROUPS OF BIFURCATION LESIONS BASED ON THEIR ANATOMICAL CHARACTERISTICS.
Authors: Ilias Nikolakopoulos, Evangelia Vemmou, Judit Karacsonyi, Spyridon Kostantinis, Bahadir Simsek, Bavana V. Rangan, Santiago Garcia, M. Nicholas Burke, Mario Goessl, Anil K. Poulose, Jay H. Traverse, Paul Sorajja, Yale L. Wang, Ivan J. Chavez, Gerasimos Siasos, Dimitris Tousoulis, Konstantinos Tsioufis, Emmanouil S. Brilakis
Journal: Journal of the American College of Cardiology (2022)
MULTICOMPONENT GERIATRIC INTERVENTION FOR FRAIL HOSPITALIZED OLDER ADULTS WITH CARDIOVASCULAR DISEASE: THE TARGET-EFT RANDOMIZED CLINICAL TRIAL
Authors: Rosie Fountotos, Fayeza Ahmad, Haroon Munir, Neetika Bharaj, Kiana Hagerty, Mojdeh M. Hedjazi, John Marsala, Lawrence G. Rudski, Michael Goldfarb, Jonathan Afilalo
Journal: Journal of the American College of Cardiology (2022)
Adjuvant PD-1 Blockade in Resected Melanoma: Is Preventing Recurrence Enough?
Authors: James W. Smithy, Alexander N. Shoushtari
Journal: Cancer Discovery (2022)

Summary: Grossmann and colleagues report the results of a large randomized trial demonstrating improved recurrence-free survival with adjuvant pembrolizumab in resected melanoma compared with adjuvant ipilimumab or IFNα2b. However, it remains unclear whether adjuvant immunotherapies extend overall survival as outcomes for patients with advanced melanoma continue to improve. See related article by Grossmann et al., p. 644 (1).
Risk factors associated with an outbreak of COVID-19 in a meat processing plant in southern Germany, April to June 2020
Authors: Iris Finci, Remo Siebenbaum, Josephin Richtzenhain, Angelika Edwards, Carina Rau, Jonas Ehrhardt, Linda Koiou, Brigitte Joggerst, Stefan O Brockmann
Journal: Eurosurveillance (2022)

Meat processing plants have been prominent hotspots for coronavirus disease (COVID-19) outbreaks around the world. We describe infection prevention measures and risk factors for infection spread at a meat processing plant in Germany with a COVID-19 outbreak from April to June 2020. We analysed a cohort of all employees and defined cases as employees with either a PCR or ELISA positive result. Of 1,270 employees, 453 (36%) had evidence of SARS-CoV-2 infection. The highest attack rates were observed in meat processing and slaughtering areas. Multivariable analysis revealed that being a subcontracted employee (adjusted risk ratio (aRR)): 1.43, 95% CI: 1.06-1.96), working in the meat cutting area (aRR: 2.44, 95% CI: 1.45-4.48), working in the slaughtering area (aRR: 2.35, 95% CI: 1.32-4.45) and being a veterinary inspector (aRR: 4.77, 95% CI: 1.16-23.68) increased infection risk. Sharing accommodation or transportation were not identified as risk factors for infection. Our results suggest that workplace was the main risk factor for infection spread. These results highlight the importance of implementing preventive measures targeting meat processing plants. Face masks, distancing, staggering breaks, increased hygiene and regular testing for SARS-CoV2 helped limit this outbreak, as the plant remained open throughout the outbreak.
A MODIFIED OESIL SCORE IDENTIFIES HIGH-RISK PATIENTS WITH SYNCOPE
Authors: Carissa Pistilli, Advay G. Bhatt, Muhammadali Habibi, Mark William Preminger, Tina C. Sichrovsky, Suneet Mittal, Dan Laurentiu Musat, Aleksandra Bozovic, Laura Flynn, Nurten Fidan, Erica M. Wisely
Journal: Journal of the American College of Cardiology (2022)
THE LONG-TERM PROGNOSTIC SIGNIFICANCE OF ECHOCARDIOGRAPHY FINDINGS IN COVID-19 PATIENTS
Authors: Lior Lupu, Ariel Banai, Ariel Borohovitz, Erez Levy, Eihab Ghantous, Philippe Taieb, Yael Lichter, Sapir Sadon, Aviram Hochstadt, Orly Sapir, Yoav Granot, Ilan Merdler, Merav Ingbir, Yaron Arbel, Michal Laufer-Perl, Shmuel Banai, Yishay Szekely, Yan Topilsky
Journal: Journal of the American College of Cardiology (2022)
Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization
Authors: Zhangkai J. Cheng, Huimin Huang, Peiyan Zheng, Mingshan Xue, Jing Ma, Zhiqing Zhan, Hui Gan, Yifeng Zeng, Runpei Lin, Shiyun Li, Ruifen Zhong, Siping Li, Hongman Wang, Baoqing Sun
Journal: Allergy (2022)

Abstract Background The inactivated Sinopharm/BBIBP COVID‐19 vaccine has been widely used in the world and has joined the COVAX vaccine supply program for developing countries. It is also well adapted for usage in low‐ and middle‐income nations due to their low storage requirements. Objective This study aims to report on the kinetics, durability, and neutralizing ability of the induced immunity of the BBIBP vaccine, and the intensified antibody response elicited by the booster. Methods A total of 353 healthy adult participants, aged 20–74 years, were recruited in this multicenter study. A standard dose of the BBIBP vaccine was administered (Month 0), followed by a second standard dose (Month 1), and a booster dose (after Month 7). Vaccine‐induced virus‐specific antibody levels (SARS‐CoV‐2‐IgA/IgM/IgG), conventional virus neutralization test (cVNT), pseudovirus neutralization test (pVNT), and surrogate virus neutralization test (sVNT) were monitored over multiple time points. Results Neutralizing titers induced by the two doses of inactivated vaccine for COVID‐19 peaked at Month 2 and declined to 33.89% at Month 6. Following the booster dose, elevated levels of antibodies were induced for IgA, IgG, and neutralizing antibodies, with neutralizing titer reaching 13.2 times that of before the booster. Conclusion By monitoring the antibody titer levels postvaccination, this study has shown that serum antibody levels will decrease over time, but a notable spike in antibody levels postbooster highlights the anamnestic immune response. This signifies that the protection capability has increased following the injection of booster immunization.
Fast and sensitive detection of SARS-CoV-2 RNA using suboptimal protospacer adjacent motifs for Cas12a
Authors: Shuhan Lu, Xiaohan Tong, Yang Han, Kun Zhang, Yizhou Zhang, Qiubing Chen, Junyi Duan, Xinlin Lei, Muhan Huang, Yang Qiu, Ding-Yu Zhang, Xi Zhou, Ying Zhang, Hao Yin
Journal: Nature Biomedical Engineering (2022)
Switching to the cyclic pentose phosphate pathway powers the oxidative burst in activated neutrophils
Authors: Emily C. Britt, Jorgo Lika, Morgan A. Giese, Taylor J. Schoen, Gretchen L. Seim, Zhengping Huang, Pui Y. Lee, Anna Huttenlocher, Jing Fan
Journal: Nature Metabolism (2022)

Abstract Neutrophils are cells at the frontline of innate immunity that can quickly activate effector functions to eliminate pathogens upon stimulation. However, little is known about the metabolic adaptations that power these functions. Here we show rapid metabolic alterations in neutrophils upon activation, particularly drastic reconfiguration around the pentose phosphate pathway, which is specifically and quantitatively coupled to an oxidative burst. During this oxidative burst, neutrophils switch from glycolysis-dominant metabolism to a unique metabolic mode termed ‘pentose cycle’, where all glucose-6-phosphate is diverted into oxidative pentose phosphate pathway and net flux through upper glycolysis is reversed to allow substantial recycling of pentose phosphates. This reconfiguration maximizes NADPH yield to fuel superoxide production via NADPH oxidase. Disruptions of pentose cycle greatly suppress oxidative burst, the release of neutrophil extracellular traps and pathogen killing by neutrophils. Together, these results demonstrate the remarkable metabolic flexibility of neutrophils, which is essential for their functions as the first responders in innate immunity.
Missed Signs of Acute Pulmonary Embolism in Electrocardiogram Findings−Reply
Authors: Ian S. deSouza, Jane Belyavskaya
Journal: JAMA Internal Medicine (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal